M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance PharmaphorumInsilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates. Neuroscience Read full story Post navigation Previous: Post-marketing oncology studies: Enabling faster recruitment and lower costsNext: Boehringer advances duo for aggressive cancers into phase 3 Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
